Telix Pharmaceuticals Limited Stock Probability of Future Pink Sheet Price Finishing Under 12.69
| TLPPF Stock | USD 16.00 0.82 5.40% |
Telix |
Telix Pharmaceuticals Target Price Odds to finish below 12.69
The tendency of Telix Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 12.69 or more in 90 days |
| 16.00 | 90 days | 12.69 | under 4 |
Based on a normal probability distribution, the odds of Telix Pharmaceuticals to drop to $ 12.69 or more in 90 days from now is under 4 (This Telix Pharmaceuticals Limited probability density function shows the probability of Telix Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Telix Pharmaceuticals price to stay between $ 12.69 and its current price of $16.0 at the end of the 90-day period is about 89.56 .
Assuming the 90 days horizon Telix Pharmaceuticals Limited has a beta of -0.15. This usually implies as returns on the benchmark increase, returns on holding Telix Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Telix Pharmaceuticals Limited is likely to outperform the market. Additionally Telix Pharmaceuticals Limited has an alpha of 0.3201, implying that it can generate a 0.32 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Telix Pharmaceuticals Price Density |
| Price |
Predictive Modules for Telix Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Telix Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Telix Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Telix Pharmaceuticals is not an exception. The market had few large corrections towards the Telix Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Telix Pharmaceuticals Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Telix Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.32 | |
β | Beta against Dow Jones | -0.15 | |
σ | Overall volatility | 1.00 | |
Ir | Information ratio | 0.06 |
Telix Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Telix Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Telix Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Telix Pharmaceuticals had very high historical volatility over the last 90 days | |
| Telix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.9 M. Net Loss for the year was (80.51 M) with profit before overhead, payroll, taxes, and interest of 5.05 M. | |
| Telix Pharmaceuticals Limited has accumulated about 122.61 M in cash with (59.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Aileron Therapeutics CEO James Brian Windsor buys 897 in stock |
Telix Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Telix Pink Sheet often depends not only on the future outlook of the current and potential Telix Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Telix Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 285.1 M |
Telix Pharmaceuticals Technical Analysis
Telix Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Telix Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Telix Pharmaceuticals Limited. In general, you should focus on analyzing Telix Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Telix Pharmaceuticals Predictive Forecast Models
Telix Pharmaceuticals' time-series forecasting models is one of many Telix Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Telix Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Telix Pharmaceuticals
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Telix Pharmaceuticals had very high historical volatility over the last 90 days | |
| Telix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.9 M. Net Loss for the year was (80.51 M) with profit before overhead, payroll, taxes, and interest of 5.05 M. | |
| Telix Pharmaceuticals Limited has accumulated about 122.61 M in cash with (59.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Aileron Therapeutics CEO James Brian Windsor buys 897 in stock |
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out Telix Pharmaceuticals Backtesting, Telix Pharmaceuticals Valuation, Telix Pharmaceuticals Correlation, Telix Pharmaceuticals Hype Analysis, Telix Pharmaceuticals Volatility, Telix Pharmaceuticals History as well as Telix Pharmaceuticals Performance. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.